156 related articles for article (PubMed ID: 33982936)
1. Tissue Systems Pathology Test Objectively Risk Stratifies Barrett's Esophagus Patients With Low-Grade Dysplasia.
Frei NF; Khoshiwal AM; Konte K; Bossart EA; Stebbins K; Zhang Y; Pouw RE; Ten Kate FJW; Seldenrijk KA; Meijer SL; Critchley-Thorne RJ; Bergman JJGHM
Am J Gastroenterol; 2021 Apr; 116(4):675-682. PubMed ID: 33982936
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
3. The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia.
Khoshiwal AM; Frei NF; Pouw RE; ; Smolko C; Arora M; Siegel JJ; Duits LC; Critchley-Thorne RJ; Bergman JJGHM
Gastroenterology; 2023 Nov; 165(5):1168-1179.e6. PubMed ID: 37657759
[TBL] [Abstract][Full Text] [Related]
4. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
[TBL] [Abstract][Full Text] [Related]
5. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal outcomes of radiofrequency ablation versus surveillance endoscopy for Barrett's esophagus with low-grade dysplasia.
Kahn A; Al-Qaisi M; Kommineni VT; Callaway JK; Boroff ES; Burdick GE; Lam-Himlin DM; Temkit M; Vela MF; Ramirez FC
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29036431
[TBL] [Abstract][Full Text] [Related]
7. Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Nondysplastic Barrett's Esophagus: A Spatial-Temporal Analysis.
Frei NF; Konte K; Bossart EA; Stebbins K; Zhang Y; Pouw RE; Critchley-Thorne RJ; Bergman JJGHM
Clin Transl Gastroenterol; 2020 Oct; 11(10):e00244. PubMed ID: 33108124
[TBL] [Abstract][Full Text] [Related]
8. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
[TBL] [Abstract][Full Text] [Related]
9. Low-grade dysplasia diagnosis ratio and progression metrics identify variable Barrett's esophagus risk stratification proficiency in independent pathology practices.
Davison JM; Shah MB; Deitrick C; Chennat J; Fasanella KE; McGrath K
Gastrointest Endosc; 2018 Nov; 88(5):807-815.e2. PubMed ID: 29944863
[TBL] [Abstract][Full Text] [Related]
10. A Tissue Systems Pathology Test Outperforms the Standard-of-Care Variables in Predicting Progression in Patients With Barrett's Esophagus.
Davison JM; Goldblum JR; Duits LC; Khoshiwal AM; Bergman JJ; Falk GW; Diehl DL; Khara HS; Smolko C; Arora M; Siegel JJ; Critchley-Thorne RJ; Thota PN
Clin Transl Gastroenterol; 2023 Nov; 14(11):e00631. PubMed ID: 37622544
[TBL] [Abstract][Full Text] [Related]
11. Improved Progression Prediction in Barrett's Esophagus With Low-grade Dysplasia Using Specific Histologic Criteria.
Ten Kate FJC; Nieboer D; Ten Kate FJW; Doukas M; Bruno MJ; Spaander MCW; Looijenga LHJ; Biermann K;
Am J Surg Pathol; 2018 Jul; 42(7):918-926. PubMed ID: 29697438
[TBL] [Abstract][Full Text] [Related]
12. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
[TBL] [Abstract][Full Text] [Related]
14. Management of low-grade dysplasia in Barrett's esophagus.
Wani S
Curr Opin Gastroenterol; 2012 Jul; 28(4):370-6. PubMed ID: 22508323
[TBL] [Abstract][Full Text] [Related]
15. Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists.
Moole H; Patel J; Ahmed Z; Duvvuri A; Vennelaganti S; Moole V; Dharmapuri S; Boddireddy R; Yedama P; Bondalapati N; Uppu A; Vennelaganti P; Puli S
World J Gastroenterol; 2016 Oct; 22(39):8831-8843. PubMed ID: 27818599
[TBL] [Abstract][Full Text] [Related]
16. Risk of progression in Barrett's esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland.
Huhta H; Melkko J; Kuopio T; Karttunen TJ; Helminen O
Scand J Gastroenterol; 2022 Sep; 57(9):1024-1029. PubMed ID: 35450519
[TBL] [Abstract][Full Text] [Related]
17. Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus.
Nayna L; Emma W; Vani K
Curr Opin Gastroenterol; 2016 Jul; 32(4):294-301. PubMed ID: 27070914
[TBL] [Abstract][Full Text] [Related]
18. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
19. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG
J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452
[TBL] [Abstract][Full Text] [Related]
20. Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients With Barrett's Esophagus.
Davison JM; Goldblum J; Grewal US; McGrath K; Fasanella K; Deitrick C; DeWard AD; Bossart EA; Hayward SL; Zhang Y; Critchley-Thorne RJ; Thota PN
Am J Gastroenterol; 2020 Jun; 115(6):843-852. PubMed ID: 32079863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
